Tezspire (tezepelumab-ekko) is an injectable biologic developed by AstraZeneca and co-commercialized in the US with Amgen. It blocks thymic stromal lymphopoietin, a signal that sits upstream of several inflammation pathways, which is why it is the one severe-asthma biologic labeled without a phenotype or biomarker requirement. FDA labeling covers severe asthma and inadequately controlled chronic rhinosinusitis with nasal polyps in patients 12 and older.
The dose is a single 210 mg injection every four weeks, so a year of treatment is 13 doses and there is no dose escalation to model. What changes the bill is which device is prescribed and who pushes the plunger. Every figure below was verified on September 2, 2026, and this page covers money and paperwork only, not whether the drug is right for you.
What Does Tezspire Cost Without Insurance?
Tezspire’s own cost page publishes the list price for two of the three presentations. The Texas Department of State Health Services collects January 1 wholesale acquisition cost directly from manufacturers and publishes it in the 2026 Annual WAC Report, and its two Amgen entries match the manufacturer page to the cent. The Medicare row comes from the CMS Part B payment limit file effective July 1 through September 30, 2026, built on first-quarter 2026 average sales price data.
| Tezspire presentation or benchmark | Low | Average / typical | High |
|---|---|---|---|
| 210 mg prefilled syringe, list price | $4,587.41 | $4,587.41 | $4,587.41 |
| 210 mg prefilled pen, list price | $4,908.93 | $4,908.93 | $4,908.93 |
| Medicare Part B allowed amount, 210 mg (Q3 2026) | $3,763.20 | $3,763.20 | $3,763.20 |
| In-office injection administration, CPT 96372 (Medicare national) | $15.36 | $15.40 | $15.44 |
| TEZSPIRE Together Co-Pay Program (commercial insurance only) | $0 | $0 | $0 |
| Amgen Safety Net Foundation (approved uninsured applicants) | $0 | $0 | $0 |
The honest cross-source range for one 210 mg dose of the drug itself is $3,763 to $4,909. Over 13 doses a year, that is $48,921.60 at the Medicare benchmark, $59,636.33 at the syringe list price and $63,816.09 at the pen list price. Tezspire’s own page puts it plainly: most patients do not pay the list price.
Why the pen costs $321.52 more than the syringe
Identical drug, identical 210 mg, identical schedule. The pen carries a $321.52 premium per dose, which is $4,179.76 a year, purely for the delivery device and the ability to inject at home. That premium is worth paying if it removes 13 clinic visits from your year. It is not worth paying if a clinician was going to give the injection anyway.
There is also a single-dose vial in the FDA labeling, and it does not appear in either the manufacturer’s published prices or the Texas disclosure, so this guide does not quote a number for it. If a clinic proposes the vial, ask for the price in writing rather than assuming it tracks the syringe.
The administration fee is the small number, the facility fee is not
CPT 96372, the code for a therapeutic subcutaneous injection, carries 0.46 total relative value units in the CMS 2026 physician fee schedule file released June 30, 2026. Against the 2026 conversion factors of $33.4009 and $33.5675, that is about $15.36 to $15.44 nationally. Amgen’s copay program offers up to $100 a month toward in-office administration costs for the prefilled syringe, which is a fair ceiling for what a physician office bills.
A hospital outpatient department is the expensive venue, because it bills its own facility charge on top of the drug and the injection, and no national file will tell you that number in advance. Our guide to hospital price transparency explains how to pull a hospital’s posted cash rate before you commit to being treated there.
What Drives the Price
Which device the prescription names. Syringe at $4,587.41, pen at $4,908.93. That decision is made when the prescription is written, and it is easy to change before the first fill.
Where the injection happens. Home pen injection costs the drug and nothing else. A physician office adds roughly $15 of Medicare-benchmarked administration. A hospital outpatient clinic adds an unposted facility fee. Site of care moves the number more than anything except the assistance programs.
Your insurance category, not just whether you have insurance. The copay card is open to commercially insured patients regardless of income and with no financial documentation, and closed to everyone paying cash. The free-drug program is the mirror image: it exists specifically for people with no coverage. If you sit between the two, with a commercial plan that nominally covers Tezspire at 40% specialty coinsurance, the copay card is doing the heavy lifting.
There is no biosimilar. FDA’s biosimilar product list, content current as of August 4, 2026, contains no tezepelumab product. Tezspire was first approved in December 2021, so it is early in its exclusivity life and nothing cheaper is coming soon.
No dose or phenotype variation. Unlike some biologics in this class, Tezspire has one adult and adolescent dose, 210 mg every four weeks, with no weight banding and no loading dose. That makes the annual cost easy to forecast but also removes the possibility of a cheaper schedule.
Cash Price vs. Insurance
Tezspire is a clean example of a drug where the cash market barely exists. It is a specialty biologic distributed through limited channels, not something a neighborhood pharmacy stocks, and a discount card does very little against a list price near $4,600.
If you have commercial insurance, run the claim and enroll in the TEZSPIRE Together Co-Pay Program. Amgen advertises as little as $0 per dose, states there are no income requirements and no financial documentation needed, and adds up to $100 a month toward in-office administration for the prefilled syringe. Program maximums apply, and the posted terms exclude anyone paying cash.
If you are uninsured, skip the shopping and go straight to the Amgen Safety Net Foundation. The foundation says it provides access to every patient who qualifies, and the qualification test is income plus lack of coverage rather than a lottery. That is a materially better deal than any price you could negotiate.
If a quote from a clinic or specialty pharmacy matches nothing on this page, run it through our fair price checker before you agree to it.
How to Pay Less
-
Apply to the Amgen Safety Net Foundation before you pay anything. The published income guidelines run from $47,880 for a household of one to $99,000 for four, plus $17,040 for each additional person, with a second, higher table reaching $79,800 to $165,000 for certain products. You need no insurance coverage for the medicine (or a qualifying Medicare affordability gap for some products) and six months of US or territory residency. TEZSPIRE Together can start the conversation at 888-897-7473, and Amgen SupportPlus at 866-264-2778.
-
Pick the device and the site of care on purpose. The syringe saves $321.52 a dose against the pen, but only the pen is labeled for patient or caregiver injection at home. Price both routes as a package: syringe plus 13 office visits versus pen plus zero. Then ask the office for its cash administration charge in writing, and refuse a hospital outpatient referral unless someone can quote the facility fee.
-
Call a community health center before you call a specialty clinic. Safety-net providers often buy specialty drugs through federal discount programs and run a sliding fee scale on the visit itself, so both halves of the bill can land lower. Our guide to free and sliding-scale clinics covers how to find one and what to ask when you call, and our Nucala guide explains how the federal 340B discount program changes what a covered clinic pays for a biologic like this one.
-
Check whether a copay foundation is actually open before you apply. These funds run out of money and close. The HealthWell Foundation’s asthma fund is currently listed as closed, described as temporarily closed to new patients for lack of sufficient funding, while its bronchiectasis fund is open. Most of these charities also require you to have insurance that covers part of the drug, which sends uninsured applicants back to the manufacturer program anyway.
-
Work the bill you already have. If an invoice landed before assistance was approved, start with an itemized hospital bill so the drug charge and the facility charge are separated, then use our medical bill negotiation guide. Hospital charity care can erase the facility side entirely, and our charity care checker will tell you whether you are likely to qualify. If a bill has already gone to collections, our guide to medical bills in collections covers what to do next.
-
Confirm the cheaper layers are genuinely exhausted. Biologics sit at the top of a very steep ladder. Our guides to inhaler costs, Symbicort, Breztri, Advair, Spiriva, Trelegy, montelukast and albuterol without insurance show what the maintenance and rescue layers cost in cash.
Bottom Line
Budget $3,763 to $4,909 for one 210 mg dose of Tezspire in September 2026, plus about $15 if a physician office gives the injection and an unknown facility fee if a hospital does. Across 13 doses a year that is roughly $48,900 at the Medicare benchmark and $59,600 to $63,800 at list.
For an uninsured patient the target is not a cheaper price, it is zero through the Amgen Safety Net Foundation, and the application is worth making even if you assume your income disqualifies you. For the other severe-asthma biologic priced the same way, see our guide to Nucala, and for the type-2 biologic that competes with both across asthma, nasal polyps and COPD, see Dupixent.